Cancer patients can respond very differently to the same treatment, while current testing may not reliably identify the therapy most likely to work for each tumor.
R&D Focus
Casinvent Pharma develops therapeutic options for the treatment of selected malignancies
Innovative Solution
Casinvent Pharma provides pharmaceutical solutions for the treatment of selected malignancies. It is based on the use of proprietary selective inhibitors of enzymes from the CK1 family for leukemia cell migration into lymphoid organs.
Casinvent Pharma provides pharmaceutical solutions for the treatment of selected malignancies. It is based on the use of proprietary selective inhibitors of enzymes from the CK1 family for leukemia cell migration into lymphoid organs.
Something missing or incorrect on this page? Help us enrich this information
